For instance, the delivery of anti-inflammatory drugs and insulin sensitizers through EVs can significantly ameliorate the inflammatory state and enhance insulin sensitivity in patients with PCOS, ultimately leading to improved treatment outcomes (104–106). This evidence concerns the gene INS and polycystic ovary syndrome.